EU opens antitrust investigation into Vifor Pharma for trashing rival Pharmacosmos

The EU Commission is concerned that Vifor Pharma might have abused a ”dominant position” by spreading false safety information about its closest European competitor on the IV iron treatment market, Pharmacosmos.

Margrethe Vestager, EU Commissioner for Competition | Photo: Jennifer Jacquemart / European Union/European Commission

Monofer, an iron deficiency drug developed by Pharmacosmos, might have faced unfair conditions on the European market for years due to possible disparaging attempts by Vifor Pharma, according to the EU Commission, whose concerns have now led to a formal antitrust investigation into the matter.

In a press release, the Commission says it appears that the Swiss firm has attempted to stifle competition for its own blockbuster drug, Ferinject, an intravenous (IV) iron deficiency treatment, by spreading false information about Monofer’s safety, which is Vifor Pharma’s ”closest – and potentially only – competitor in Europe.”

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs